Autres langues Merck & Co., Inc.

Actions

MRK

US58933Y1055

Marché Fermé - Nyse Autres places de cotation 22:00:45 14/05/2024			Pré-ouverture 01:50:01
128,7 ^USD	-0,49 %		130,5	+1,43 %

14/05	La FDA américaine refuse d'approuver l'utilisation élargie du vaccin contre l'hépatite B de Dynavax	RE
13/05	Merck : arrêt d'un essai de phase 3 dans le mélanome	CF

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine	14/05
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14/05
Merck : arrêt d'un essai de phase 3 dans le mélanome	13/05
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study	13/05
Merck Halts Drug Combination Arm of Study Testing Potential Melanoma Treatment	13/05
Merck stops skin cancer combination therapy testing in late-stage study	13/05
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma	13/05
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA plus Chemotherapy, With or Without Radiotherapy, for Patients with Newly Diagnosed, High-Risk Endometrial Cancer	10/05
Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma	09/05
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	09/05
MÄRKTE USA/Weiter wenig Bewegung - Arm sehr schwach	09/05
Merck : échec d'un essai dans le cancer de l'endomètre	09/05
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint	09/05
Merck's Late-Stage Study for Cancer Drug Keytruda Plus Chemotherapy Fails to Meet Primary Endpoint	09/05
Merck : succès de l'initiative 'Merck for Mothers'	09/05
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy	09/05
Health Canada Approves Merck & Co., Inc.'s Keytruda® for Adult Patients with Locally Advanced Unresectable or Metastatic Biliary Tract Carcinoma, in Combination with Gemcitabine-Based Chemotherapy	09/05
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent	09/05
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy	09/05
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	08/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Merck & Co., Inc. : Une vache à lait qui cache des vedettes

Le 11 juillet 2022 à 11:12